109 related articles for article (PubMed ID: 23116743)
1. Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis.
Bera E; Mia R
S Afr Med J; 2012 Oct; 102(11 Pt 1):855-9. PubMed ID: 23116743
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
[TBL] [Abstract][Full Text] [Related]
4. Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.
Aaron E; Kempf MC; Criniti S; Tedaldi E; Gracely E; Warriner A; Kumar R; Bachmann LH
PLoS One; 2010 Sep; 5(9):e12617. PubMed ID: 20838641
[TBL] [Abstract][Full Text] [Related]
5. Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.
Peters PJ; Polle N; Zeh C; Masaba R; Borkowf CB; Oyaro B; Omolo P; Ogindo P; Ndivo R; Angira F; Lando R; Fowler MG; Weidle PJ; Thomas TK
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(2):142-9. PubMed ID: 22020069
[TBL] [Abstract][Full Text] [Related]
6. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
Jamisse L; Balkus J; Hitti J; Gloyd S; Manuel R; Osman N; Djedje M; Farquhar C
J Acquir Immune Defic Syndr; 2007 Apr; 44(4):371-6. PubMed ID: 17259905
[TBL] [Abstract][Full Text] [Related]
8. Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.
Ouyang DW; Brogly SB; Lu M; Shapiro DE; Hershow RC; French AL; Leighty RM; Thompson B; Tuomala RE
AIDS; 2010 Jan; 24(1):109-14. PubMed ID: 19926957
[TBL] [Abstract][Full Text] [Related]
9. Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis.
Ford N; Calmy A; Andrieux-Meyer I; Hargreaves S; Mills EJ; Shubber Z
AIDS; 2013 Apr; 27(7):1135-43. PubMed ID: 23299174
[TBL] [Abstract][Full Text] [Related]
10. Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital.
Kondo W; Carraro EA; Prandel E; Dias JM; Perini J; Macedo RL; Cornelsen TC; Sbalquiero R; Sasaki Md
Braz J Infect Dis; 2007 Dec; 11(6):544-8. PubMed ID: 18327464
[TBL] [Abstract][Full Text] [Related]
11. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine.
Chi BH; Sinkala M; Stringer EM; Cantrell RA; Mtonga V; Bulterys M; Zulu I; Kankasa C; Wilfert C; Weidle PJ; Vermund SH; Stringer JS
AIDS; 2007 May; 21(8):957-64. PubMed ID: 17457089
[TBL] [Abstract][Full Text] [Related]
12. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
Siegfried N; Uthman OA; Rutherford GW
Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
[TBL] [Abstract][Full Text] [Related]
13. Experience of nevirapine use in a London cohort of HIV-infected pregnant women.
Edwards SG; Larbalestier N; Hay P; de Ruiter A; Welch J; Taylor GP; Easterbrook P
HIV Med; 2001 Apr; 2(2):89-91. PubMed ID: 11737384
[TBL] [Abstract][Full Text] [Related]
14. Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
Bock P; Fatti G; Grimwood A
Int Health; 2013 Jun; 5(2):132-8. PubMed ID: 24030113
[TBL] [Abstract][Full Text] [Related]
15. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL.
Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Inthong Y; Prasithsirikul W; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chumpathat N; Termvises P; Chaovavanich A
Int J STD AIDS; 2007 Nov; 18(11):782-6. PubMed ID: 18005514
[TBL] [Abstract][Full Text] [Related]
17. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
João EC; Calvet GA; Menezes JA; D'Ippolito MM; Cruz ML; Salgado LA; Matos HJ
Am J Obstet Gynecol; 2006 Jan; 194(1):199-202. PubMed ID: 16389032
[TBL] [Abstract][Full Text] [Related]
18. Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
Snijdewind IJ; Smit C; Godfried MH; Nellen JF; de Wolf F; Boer K; van der Ende ME
J Infect; 2012 Apr; 64(4):409-16. PubMed ID: 22227465
[TBL] [Abstract][Full Text] [Related]
19. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.
Hitti J; Frenkel LM; Stek AM; Nachman SA; Baker D; Gonzalez-Garcia A; Provisor A; Thorpe EM; Paul ME; Foca M; Gandia J; Huang S; Wei LJ; Stevens LM; Watts DH; McNamara J;
J Acquir Immune Defic Syndr; 2004 Jul; 36(3):772-6. PubMed ID: 15213559
[TBL] [Abstract][Full Text] [Related]
20. Third-trimester maternal toxicity with nevirapine use in pregnancy.
Joy S; Poi M; Hughes L; Brady MT; Koletar SL; Para MF; Fan-Havard P
Obstet Gynecol; 2005 Nov; 106(5 Pt 1):1032-8. PubMed ID: 16260522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
